請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19068
標題: | 發展抗表皮生長因子受體人類單鍊抗體結合藥物傳輸系統於頭頸部鱗狀細胞癌之標靶治療 Development of Anti-EGFR scFv-mediated Drug Delivery Systems for Targeted Therapy of Head and Neck Squamous Cell Carcinoma |
作者: | Meng-Jhe Chung 鍾孟哲 |
指導教授: | 吳漢忠,江俊斌 |
關鍵字: | 頭頸部癌,表皮生長因子受體,單鍊免疫球蛋白變異區段,藥物傳輸系統, head and neck cancer,EGFR,scFv,drug delivery systems, |
出版年 : | 2016 |
學位: | 碩士 |
摘要: | 表皮生長因子受體 (EGFR)為erbB家族中的一員,在過去的文獻中發現其參與在數種癌症的發生與惡化。在30%上皮細胞癌中EGFR有突變、基因重複或是錯誤調節。因此研發專一性針對EGFR的標靶治療是具有前景的治療方式。本實驗室先前利用噬菌體顯示法 (phage display) 挑選出兩株能夠專一性結合表皮生長因子受體外域 (EGFR-Ex) 之人類單鍊免疫球蛋白變異區段 (scFv)。將標的表皮生長因子受體之人類單鍊免疫球蛋白變異區段與微脂體進行鍵結後,發現能提升微脂體與肝癌、肺癌以及頭頸部癌細胞株結合和內化。將此標的物與包裹藥物之微脂體進行鍵結後發現標的之微脂體與未標的之微脂體相比能更加有效毒殺癌細胞。接著以活體內腫瘤導向,發現能有效與腫瘤細胞結合。於治療異體移植頭頸部癌之免疫缺陷小鼠中,發現接上此標物物後能更加有效提升小鼠之存活。綜合上續之結果,發現標的表皮生長因子受體人類單鍊免疫球蛋白變異區段之微脂體藥物能更加有效提升藥物傳輸於治療頭頸部癌。 Epidermal growth factor receptor, a member of the ErbB family, has been reported to involve in pathogenesis and progression in a plethora of cancer types. Genetic aberration of EGFR such as activating mutation and amplification are implicated in about 30% of all epithelial cancers including head and neck squamous cell carcinoma (HNSCC). Therefore, it is rational and promising to develop a targeted regimen toward this receptor. Previous work of our laboratory acquired two novel scFvs that could specifically bind to EGFR extracellular domains (EGFR-Ex) through phage display technique. Conjugation of these two scFvs to liposome enhanced binding and internalization ability compared to non-targeting counterpart in cell lines of liver, lung and head and neck cancer cells. Furthermore, EGFR scFv-conjugated liposomal doxorubicin or vinorelbine could augment their cytotoxic effects on cancer cells. The specificity and binding ability of EGFR scFv were also verified through in vivo homing assay. In the FaDu-derived subcutaneous xenograft model, EGFR scFv-conjugated liposomal drugs reduced the tumor burden more efficiently and increased the survival rates than non-targeting liposomal drugs. Taken together, these results reveal the potential benefit of EGFR-specific scFv in respect of therapeutic enhancement of targeted drug delivery in the treatment of head and neck cancer. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19068 |
DOI: | 10.6342/NTU201602146 |
全文授權: | 未授權 |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 3.85 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。